Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininko Įsakymas

Total Page:16

File Type:pdf, Size:1020Kb

Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininko Įsakymas VALSTYBINĖS VAISTŲ KONTROLĖS TARNYBOS PRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS VIRŠININKO ĮSAKYMAS DĖL VALSTYBINĖS VAISTŲ KONTROLĖS TARNYBOS PRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS VIRŠININKO 2006 M. LAPKRIČIO 2 D. ĮSAKYMO NR. 1A-658 „DĖL TARPTAUTINIŲ PREKĖS ŽENKLU NEREGISTRUOTŲ VAISTINIŲ MEDŽIAGŲ PAVADINIMŲ ATITIKMENŲ LIETUVIŲ KALBA SĄRAŠO PATVIRTINIMO“ PAKEITIMO 2010 m. gruodžio 20 d. Nr. 1A-1355 Vilnius Atsižvelgdamas į Pasaulinės sveikatos organizacijos 2008–2010 m. paskelbtus 60-ąjį, 61-ąjį, 62-ąjį, 63-iąjį ir 64-ąjį Rekomenduojamų tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų (INN) sąrašus, p a k e i č i u Valstybinės vaistų kontrolės tarnybos prie Lietuvos Respublikos sveikatos apsaugos ministerijos viršininko 2006 m. lapkričio 2 d. įsakymą Nr. 1A-658 „Dėl Tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų atitikmenų lietuvių kalba sąrašo patvirtinimo“ (Žin., 2006, Nr. 119-4557; 2007, Nr. 43-1672; 2008, Nr. 9-330, Nr. 24-896): 1. Išdėstau preambulę taip: „Atsižvelgdamas į Lietuvos Respublikos sveikatos apsaugos ministro 2007 m. liepos 10 d. įsakymą Nr. V-596 „Dėl Vaistinių preparatų rinkodaros teisės suteikimo taisyklių, Supaprastintos homeopatinių vaistinių preparatų registravimo procedūros aprašo, Supaprastintos tradicinių augalinių vaistinių preparatų registravimo procedūros aprašo, Specialios homeopatinių vaistinių preparatų registravimo procedūros aprašo, Vaistinių preparatų rinkodaros teisės suteikimo taikant savitarpio pripažinimo ir decentralizuotą procedūras aprašo, Vaistinių preparatų analitinių, farmakotoksikologinių ir klinikinių tyrimų standartų ir protokolų, Vaistinių preparatų pakuotės ženklinimo ir pakuotės lapelio reikalavimų aprašo, Pagalbinių medžiagų, kurios turi būti nurodomos ant vaistinio preparato pakuotės ir pakuotės lapelyje, sąrašo, Vaistinio preparato rinkodaros teisės perleidimo kitam asmeniui tvarkos aprašo patvirtinimo“ (Žin., 2007, Nr. 78-3176) ir į paskelbtus Pasaulinės sveikatos organizacijos Rekomenduojamų tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų (INN) sąrašus:“. 2. Nurodytuoju įsakymu patvirtintame Tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų atitikmenų lietuvių kalba sąraše: 2.1. Išdėstau eilutę „Aceturate Aceturatas Aceturas (R)“ taip: „Aceturate Aceturatas Aceturas“ 2.2. Išdėstau eilutę „Acistrate Acistratas Acistras (R)“ taip: „Acistrate Acistratas Acistras“ 2.3. Išdėstau eilutę „Acoxil Akoksilis Acoxilum (R)“ taip: „Acoxil Akoksilis Acoxilum“ 2.4. Papildau nauja eilute, kurią po eilutės „Adargileukin alfa Adargileukinas alfa Adargileukinum alfa“ išdėstau taip: „Adarotene Adarotenas Adarotenum“ 2.5. Papildau nauja eilute, kurią po eilutės „Adenosine phosphate Adenozino fosfatas Adenosini phosphas“ išdėstau taip: „Aderbasib Aderbazibas Aderbasibum“ 2.6. Papildau nauja eilute, kurią po eilutės „Adipiodone Adipjodonas Adipiodonum“ išdėstau taip: „Adipiplon Adipiplon Adipiplonum“ 2.7. Papildau nauja eilute, kurią po eilutės „Aditoprim Aditoprimas Aditoprimum“ išdėstau taip: „Adoprazine Adoprazinas Adoprazinum“ 2.8. Papildau nauja eilute, kurią po eilutės „Adrogolide Adrogolidas Adrogolidum“ išdėstau taip: „Afacifenacin Afacifenacinas Afacifenacinum“ 2.9. Papildau naujomis eilutėmis, kurias po eilutės „Afalanine Afalaninas Afalaninum“ išdėstau taip: „Afamelanotide Afamelanotidas Afamelanotidum Afatinib Afatinibas Afatinibum Afegostat Afegostatas Afegostatum“ 2.10. Papildau nauja eilute, kurią po eilutės „Agalsidase beta Agalsidazė beta Agalsidasum beta“ išdėstau taip: „Aganirsen Aganirsenas Aganirsenum“ 2.11. Papildau nauja eilute, kurią po eilutės „Aganodine Aganodinas Aganodinum“ išdėstau taip: „Agatolimod Agatolimodas Agatolimodum“ 2.12. Papildau nauja eilute, kurią po eilutės „Alacepril Alaceprilis Alaceprilum“ išdėstau taip: „Alacizumab pegol Alacizumabas pegolas Alacizumabum pegolum“ 2.13. Įrašau eilutėje „Albiglutide Albiglutidas Albiglutidum“ vietoj žodžio „Albiglutidas“ žodį „Albigliutidas“; 2.14. Papildau nauja eilute, kurią po eilutės „Albinterferon alfa-2b Albinterferonas alfa-2b Albinterferonum alfa-2b“ išdėstau taip: „Albitiazolium bromide Albitiazolio bromidas Albitiazolii bromidum“ 2.15. Papildau nauja eilute, kurią po eilutės „Alentemol Alentemolis Alentemolum“ išdėstau taip: „Aleplasinin Aleplazininas Aleplasininum“ 2.16. Papildau nauja eilute, kurią po eilutės „Alipamide Alipamidas Alipamidum“ išdėstau taip: „Alipogene tiparvovec Alipogenas tiparvovekas Alipogenum tiparvovecum“ 2.17. Papildau nauja eilute, kurią po eilutės „Aliskiren Aliskirenas Aliskirenum“ išdėstau taip: „Alisporivir Alisporiviras Alisporivirum“ 2.18. Papildau nauja eilute, kurią po eilutės „Almokalant Almokalantas Almokalantum“ išdėstau taip: „Almorexant Almoreksantas Almorexantum“ 2.19. Papildau nauja eilute, kurią po eilutės „Amelubant Amelubantas Amelubantum“ išdėstau taip: „Amenamevir Amenameviras Amenamevirum“ 2.20. Papildau nauja eilute, kurią po eilutės „Amolanone Amolanonas Amolanonum“ išdėstau taip: „Amolimogene bepiplasmid Amolimogenas bepiplazmidas Amolimogenum bepiplasmidum“ 2.21. Papildau nauja eilute, kurią po eilutės „Amsacrine Amsakrinas Amsacrinum“ išdėstau taip: „Amsilarotene Amsilarotenas Amsilarotenum“ 2.22. Išdėstau eilutę „Amsonate Amsonatas Amsonas (R)“ taip: „Amsonate Amsonatas Amsonas“ 2.23. Papildau nauja eilute, kurią po eilutės „Amtolmetin guacil Amtolmetinas guacilas Amtolmetinum guacilum“ išdėstau taip: „Anacetrapib Anacetrapibas Anacetrapibum“ 2.24. Papildau nauja eilute, kurią po eilutės „Anpirtoline Anpirtolinas Anpirtolinum“ išdėstau taip: „Anrukinzumab Anrukinzumabas Anrukinzumabum“ 2.25. Papildau nauja eilute, kurią po eilutės „Apricitabine Apricitabinas Apricitabinum“ išdėstau taip: „Apricoxib Aprikoksibas Apricoxibum“ 2.26. Papildau nauja eilute, kurią po eilutės „Argiprestocin Argiprestocinas Argiprestocinum“ išdėstau taip: „Arhalofenate Arhalofenatas Arhalofenatum“ 2.27. Papildau naujomis eilutėmis, kurias po eilutės „Ataciguat Ataciguatas Ataciguatum“ išdėstau taip: „Atagabalin Atagabalinas Atagabalinum Ataluren Atalurenas Atalurenum“ 2.28. Papildau nauja eilute, kurią po eilutės „Atibeprone Atibepronas Atibepronum“ išdėstau taip: „Atigliflozin Atigliflozinas Atigliflozinum“ 2.29. Papildau nauja eilute, kurią po eilutės „Atiprosin Atiprozinas Atiprosinum“ išdėstau taip: „Atiratecan Atiratekanas Atiratecanum“ 2.30. Išdėstau eilutę „Axetil Aksetilas Axetilum (R)“ taip: „Axetil Aksetilas Axetilum“ 2.31. Papildau nauja eilute, kurią po eilutės „Bacmecillinam Bakmecilinamas Bacmecillinamum“ išdėstau taip: „Bafetinib Bafetinibas Bafetinibum“ 2.32. Papildau nauja eilute, kurią po eilutės „Balamapimod Balamapimodas Balamapimodum“ išdėstau taip: „Balapiravir Balapiraviras Balapiravirum“ 2.33. Papildau nauja eilute, kurią po eilutės „Bamifylline Bamifilinas Bamifyllinum“ išdėstau taip: „Baminercept Baminerceptas Baminerceptum“ 2.34. Papildau nauja eilute, kurią po eilutės „Baquiloprim Bakviloprimas Baquiloprimum“ išdėstau taip: „Barasertib Barasertibas Barasertibum“ 2.35. Papildau nauja eilute, kurią po eilutės „Barbital sodium Barbitalio natrio druska Barbitalum natricum“ išdėstau taip: „Bardoxolone Bardoksolonas Bardoxolonum“ 2.36. Papildau nauja eilute, kurią po eilutės „Beclamide Beklamidas Beclamidum“ išdėstau taip: „Beclanorsen Beklanorsenas Beclanorsenum“ 2.37. Papildau nauja eilute, kurią po eilutės „Bectumomab Bektumomabas Bectumomabum“ išdėstau taip: „Bederocin Bederocinas Bederocinum“ 2.38. Papildau nauja eilute, kurią po eilutės „Befiperide Befiperidas Befiperidum“ išdėstau taip: „Befiradol Befiradolis Befiradolum“ 2.39. Papildau nauja eilute, kurią po eilutės „Belinostat Belinostatas Belinostatum“ išdėstau taip: „Beloranib Beloranibas Beloranibum“ 2.40. Papildau nauja eilute, kurią po eilutės „Benproperine Benproperinas Benproperinum“ išdėstau taip: „Benralizumab Benralizumabas Benralizumabum“ 2.41. Papildau nauja eilute, kurią po eilutės „Bensuldazic acid Bensuldazo rūgštis Acidum bensuldazicum“ išdėstau taip: „Bentamapimod Bentamapimodas Bentamapimodum“ 2.42. Papildau nauja eilute, kurią po eilutės „Bertosamil Bertosamilas Bertosamilum“ išdėstau taip: „Berubicin Berubicinas Berubicinum“ 2.43. Papildau nauja eilute, kurią po eilutės „Bervastatin Bervastatinas Bervastatinum“ išdėstau taip: „Besifloxacin Besifloksacinas Besifloxacinum“ 2.44. Išdėstau eilutę „Besilate Besilatas Besilas (R)“ taip: „Besilate Besilatas Besilas“ 2.45. Papildau nauja eilute, kurią po eilutės „Betoxycaine Betoksikainas Betoxycainum“ išdėstau taip: „Betrixaban Betriksabanas Betrixabanum“ 2.46. Papildau nauja eilute, kurią po eilutės „Bevantolol Bevantololis Bevantololum“ išdėstau taip: „Bevasiranib Bevaziranibas Bevasiranibum“ 2.47. Išdėstau eilutę „Bezomil Bezomilis Bezomilum (R)“ taip: „Bezomil Bezomilis Bezomilum“ 2.48. Papildau nauja eilute, kurią po eilutės „Bivatuzumab Bivatuzumabas Bivatuzumabum“ išdėstau taip: „Bixalomer Biksalomeras Bixalomerum“ 2.49. Papildau nauja eilute, kurią po eilutės „Bleomycin Bleomicinas Bleomycinum“ išdėstau taip: „Blinatumomab Blinatumomabas Blinatumomabum“ 2.50. Papildau nauja eilute, kurią po eilutės „Bretylium tosilate Bretilio tozilatas Bretylii tosilas“ išdėstau taip: „Briakinumab Briakinumabas Briakinumabum“ 2.51. Papildau nauja eilute, kurią po eilutės „Brinzolamide Brinzolamidas Brinzolamidum“ išdėstau taip: „Briobacept Briobaceptas Briobaceptum“ 2.52. Išdėstau eilutę „Buciclate Buciklatas Buciclas (R)“ taip: „Buciclate Buciklatas Buciclas“ 2.53. Papildau nauja eilute, kurią po eilutės „Budesonide
Recommended publications
  • WO 2015/063180 Al 7 May 2015 (07.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/063180 Al 7 May 2015 (07.05.2015) P O P C T (51) International Patent Classification: (74) Agent: WILLIAMS, Rachel; Novozymes Biopharma UK A61K 39/00 (2006.01) C07K 16/00 (2006.01) Ltd., Castle Court, 59 Castle Boulevard, Nottingham Not A61K 39/395 (2006.01) tinghamshire NG7 1FD (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP2014/073261 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 29 October 2014 (29.10.2014) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (26) Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 190750.3 29 October 2013 (29. 10.2013) EP SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 14166865.7 2 May 2014 (02.05.2014) EP TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: NOVOZYMES BIOPHARMA DK A S (84) Designated States (unless otherwise indicated, for every [DK/DK]; Krogshoejvej 36, DK-2880 Bagsvaerd (DK).
    [Show full text]
  • Pharmacokinetics and Exposure-Response Relationship of Teprotumumab Frst 3 Months, Unless Determined to Be Medically Necessary
    Clinical Pharmacokinetics https://doi.org/10.1007/s40262-021-01003-3 ORIGINAL RESEARCH ARTICLE Pharmacokinetics and Exposure‑Response Relationship of Teprotumumab, an Insulin‑Like Growth Factor‑1 Receptor‑Blocking Antibody, in Thyroid Eye Disease Yan Xin1 · Fengyan Xu2 · Yuying Gao2 · Nivedita Bhatt1 · Jason Chamberlain1 · Saba Sile1 · Suzy Hammel1 · Robert J. Holt1 · Srini Ramanathan1 Accepted: 10 February 2021 © The Author(s) 2021 Abstract Background and Objective Thyroid eye disease (TED) is characterized by infammation/expansion of orbital tissues, prop- tosis, and diplopia. Teprotumumab is the frst US Food and Drug Administration-approved therapy for TED, administered as an initial intravenous infusion of 10 mg/kg followed by 20 mg/kg every 3 weeks for an additional seven infusions. The objec- tive of this article is to discuss the pharmacokinetics and exposure-response profle for teprotumumab in patients with TED. Methods A population pharmacokinetic analysis was performed to characterize pharmacokinetics and select dosing in patients with TED. Exposure-response was evaluated for efcacy (proptosis response, clinical activity score categorical response, and diplopia response) and safety (hyperglycemia, muscle spasms, and hearing impairment) parameters. Results Teprotumumab pharmacokinetics was linear in patients with TED, with low systemic clearance (0.334 L/day), low volume of distribution (3.9 and 4.2 L for the central and peripheral compartment, respectively), and a long elimination half- life (19.9 days). The approved dosing regimen provided > 20 µg/mL for > 90% insulin-like growth factor 1 receptor saturation throughout the dosing interval. Model-predicted mean (± standard deviation) steady-state area under the concentration-time curve, peak, and trough concentrations in patients with TED were 131 (± 30.9) mg∙h/mL, 643 (± 130) µg/mL, and 157 (± 50.6) µg/mL, respectively.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • The Role of Biological Therapy in Metastatic Colorectal Cancer After First-Line Treatment: a Meta-Analysis of Randomised Trials
    REVIEW British Journal of Cancer (2014) 111, 1122–1131 | doi: 10.1038/bjc.2014.404 Keywords: colorectal; biological; meta-analysis The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials E Segelov1, D Chan*,2, J Shapiro3, T J Price4, C S Karapetis5, N C Tebbutt6 and N Pavlakis2 1St Vincent’s Clinical School, University of New South Wales, Sydney, NSW 2052, Australia; 2Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia; 3Monash University and Cabrini Hospital, Melbourne, VIC 3800, Australia; 4The Queen Elizabeth Hospital and University of Adelaide, Woodville South, SA 5011, Australia; 5Flinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA, 5042, Australia and 6Austin Health, VIC 3084, Australia Purpose: Biologic agents have achieved variable results in relapsed metastatic colorectal cancer (mCRC). Systematic meta-analysis was undertaken to determine the efficacy of biological therapy. Methods: Major databases were searched for randomised studies of mCRC after first-line treatment comparing (1) standard treatment plus biologic agent with standard treatment or (2) standard treatment with biologic agent with the same treatment with different biologic agent(s). Data were extracted on study design, participants, interventions and outcomes. Study quality was assessed using the MERGE criteria. Comparable data were pooled for meta-analysis. Results: Twenty eligible studies with 8225 patients were identified. The use of any biologic therapy improved overall survival with hazard ratio (HR) 0.87 (95% confidence interval (CI) 0.82–0.91, Po0.00001), progression-free survival (PFS) with HR 0.71 (95% CI 0.67–0.74, Po0.0001) and overall response rate (ORR) with odds ratio (OR) 2.38 (95% CI 2.03–2.78, Po0.00001).
    [Show full text]
  • International Nonproprietary Names for Pharmaceutical Substances (INN)
    WHO Drug Information, Vol. 23, No. 2, 2009 Proposed INN: List 101 International Nonproprietary Names for Pharmaceutical Substances (INN) Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in Cumulative List No. 12, 2007 (available in CD-ROM only). The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs. Dénominations communes internationales des Substances pharmaceutiques (DCI) Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées.
    [Show full text]
  • Targeted and Novel Therapy in Advanced Gastric Cancer Julie H
    Selim et al. Exp Hematol Oncol (2019) 8:25 https://doi.org/10.1186/s40164-019-0149-6 Experimental Hematology & Oncology REVIEW Open Access Targeted and novel therapy in advanced gastric cancer Julie H. Selim1 , Shagufta Shaheen2 , Wei‑Chun Sheu3 and Chung‑Tsen Hsueh4* Abstract The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal–epithelial transition, epidermal growth factor receptor, mammalian target of rapamycin, claudin‑18.2, programmed death‑1 and DNA. Addition of trastuzumab to platinum‑ based chemotherapy has become standard of care as front‑line therapy in advanced GC overexpressing HER2. In the second‑line setting, ramucirumab with paclitaxel signifcantly improves overall survival compared to paclitaxel alone. For patients with refractory disease, apatinib, nivolumab, ramucirumab and TAS‑102 have demonstrated single‑agent activity with improved overall survival compared to placebo alone. Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability‑high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non‑inferior outcome in frst‑line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC. Keywords: Gastric cancer, Targeted therapy, Human epidermal growth factor receptor 2, Programmed death‑1, Vascular endothelial growth factor receptor 2 Background GC mortality which is consistent with overall decrease in Gastric cancer (GC), including adenocarcinoma of the GC-related deaths [4]. gastroesophageal junction (GEJ) and stomach, is the ffth Tere have been several eforts to perform large-scale most common cancer and the third leading cause of can- molecular profling and classifcation of GC.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
    Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria HEALTH SYSTEMS DIVISION Prior authorization (PA) criteria for fee-for-service prescriptions for Oregon Health Plan clients March 1, 2021 Contents Contents ................................................................................................................................................................ 2 Introduction........................................................................................................................................................... 7 About this guide ......................................................................................................................................... 7 How to use this guide ................................................................................................................................. 7 Administrative rules and supplemental information .................................................................................. 7 Update information............................................................................................................................................... 8 Effective March 1, 2021 ............................................................................................................................ 8 Substantive updates and new criteria ............................................................................................. 8 Clerical changes ............................................................................................................................
    [Show full text]
  • 5-HT2A/2C Receptor Modulation of Absence Seizures and Characterization of the GHB-Model
    5-HT2A/2C receptor modulation of absence seizures and characterization of the GHB-model A thesis submitted to Cardiff University for the degree of Doctor of Philosophy by Marcello Venzi (MSc) School of Biosciences, Cardiff University, October 2014 Chapter 1 Declaration and Statements This work has not been submitted in substance for any other degree or award at this or any other university or place of learning, nor is being submitted concurrently in candidature for any degree or other award. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 1 This thesis is being submitted in partial fulfillment of the requirements for the degree of PhD . Signed ………………………………………… (candidate) Date ………………………… STATEMENT 2 This thesis is the result of my own independent work/investigation, except where otherwise stated. Other sources are acknowledged by explicit references. The views expressed are my own. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 3 I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loan, and for the title and summary to be made available to outside organisations. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loans after expiry of a bar on access previously approved by the Academic Standards & Quality Committee. Signed ………………………………………… (candidate) Date ………………………… II Chapter 1 Summary Absence seizures (ASs) are non-convulsive epileptic events which are common in pediatric and juvenile epilepsies. They consist of EEG generalized spike-and-wave-discharges (SWDs) accompanied by an impairment of consciousness and are expressed within the thalamocortical network.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]